NCT05019794 - Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 13, 2020

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2023

Conditions

Gastric CancerGastroesophageal Junction AdenocarcinomaSolid Tumor

Interventions

DRUG

Infigratinib

Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.

Trial Locations (17)

100142

RECRUITING

Beijing Cancer Hospital ( Department of Thoracic Oncology ), Beijing

RECRUITING

Beijing Cancer Hospital (Department of Gynecological Oncology), Beijing

RECRUITING

Beijing Cancer Hospital, Beijing

110042

RECRUITING

Liaoning Cancer Hospital & Institute, Shenyang

150081

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

200032

RECRUITING

Zhongshan Hospital Fudan University, Shanghai

210008

RECRUITING

Nanjing Drum Tower Hospital, Nanjing

213004

RECRUITING

The First People's Hospital of Changzhou, Changzhou

310003

RECRUITING

The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

310016

RECRUITING

Sir Run Run Shaw hospital, Zhejiang University school of Medicine, Hangzhou

350001

RECRUITING

Fujian Medical University Union Hospital, Fuzhou

350014

RECRUITING

Fujian Cancer Hospital, Fuzhou

430079

RECRUITING

Hubei Cancer Hospital, Wuan

450008

RECRUITING

Henan Cancer Hospital, Henan

510655

RECRUITING

The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou

071030

RECRUITING

Affiliated Hospital of Hebei University, Baoding

030013

RECRUITING

Shanxi Provincial Cancer Hospital, Taiyuan